SLC7A11,在肺腺癌中是一种潜在的免疫治疗点
Qingqing Shan1, Chi Zhang1, Yangke Li2
1Department of Respiration, Chengdu First People's Hospital, No. 18, Wangxiang North Road, High-Tech Zone, Chengdu, 610041, Sichuan Province, People's Republic of China.
Scientific reports
|October 25, 2023
概括
溶性载体家族7成员11 (SLC7A11) 在肺腺癌 (LUAD) 中过度表达,与生存率较差相关. 较低的SLC7A11表达与增强的抗瘤免疫力有关,这表明它是治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 溶性载体家族7成员11 (SLC7A11) 与癌症进展有关.
- 它在肺腺癌 (LUAD) 的免疫微环境中的作用仍然在很大程度上未被探索.
研究的目的:
- 为了研究SLC7A11在LUAD中的表达.
- 确定SLC7A11对LUAD预后和瘤免疫力的影响.
- 探索SLC7A11与免疫细胞,检查点和信号通路的相关性.
主要方法:
- 利用癌症基因组图集和基因表达总汇数据库来获取表达和生存数据.
- 对差异表达基因 (DEGs) 进行了基因本体学 (GO) 和KEGG通路分析.
- 进行基因组丰富分析 (GSEA),并使用R和TISIDB分析了免疫细胞透,检查点和化学因子.
主要成果:
- 发现SLC7A11在LUAD中过度表达,高表达与5年整体存活率下降有关.
- 凯格分析显示铁亡途径的丰富,而GSEA表明SLC7A11-low组的生存途径的丰富.
- 低SLC7A11组表现出更高的免疫分数,增加了免疫检查点表达,以及与CD8+T细胞,树突细胞和各种化学因子受体的显著负相关性.
结论:
- SLC7A11表达显著影响LUAD预后和瘤免疫微环境.
- SLC7A11与关键的抗瘤免疫成分有负相关性.
- 在LUAD中,SLC7A11代表了调节瘤免疫力的潜在治疗标.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
476
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K